Forsta AP Fonden lowered its place in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.8% within the 2nd quarter, in keeping with the corporate in its most up-to-date disclosure with the Securities and Trade Fee (SEC). The fund owned 584,738 shares of the corporate’s inventory after promoting 49,200 shares throughout the interval. Johnson & Johnson makes up roughly 0.8% of Forsta AP Fonden’s funding portfolio, making the inventory its nineteenth largest holding. Forsta AP Fonden’s holdings in Johnson & Johnson had been value $85,465,000 on the finish of the latest quarter.
Quite a few different hedge funds have additionally lately modified their holdings of JNJ. Innealta Capital LLC bought a brand new stake in Johnson & Johnson within the 2nd quarter valued at about $27,000. Christopher J. Hasenberg Inc bought a brand new stake in shares of Johnson & Johnson within the first quarter valued at roughly $31,000. MFA Wealth Advisors LLC purchased a brand new place in Johnson & Johnson within the second quarter value roughly $43,000. Vermillion & White Wealth Administration Group LLC bought a brand new place in Johnson & Johnson throughout the 4th quarter value $44,000. Lastly, Grayhawk Funding Methods Inc. raised its place in Johnson & Johnson by 528.6% throughout the 4th quarter. Grayhawk Funding Methods Inc. now owns 308 shares of the corporate’s inventory valued at $48,000 after buying an extra 259 shares within the final quarter. Institutional buyers personal 69.55% of the corporate’s inventory.
Analysts Set New Value Targets
A number of analysts lately weighed in on the corporate. TD Cowen decreased their value goal on Johnson & Johnson from $195.00 to $185.00 and set a “purchase” score for the corporate in a report on Thursday, July 18th. Cantor Fitzgerald reaffirmed an “chubby” score and issued a $215.00 value goal on shares of Johnson & Johnson in a analysis report on Monday, September ninth. The Goldman Sachs Group lower their value goal on shares of Johnson & Johnson from $160.00 to $155.00 and set a “impartial” score on the inventory in a report on Friday, July nineteenth. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” score to a “impartial” score and lowered their goal value for the inventory from $160.00 to $150.00 in a report on Tuesday, July twenty third. Lastly, Daiwa America lowered Johnson & Johnson from a “strong-buy” score to a “maintain” score in a analysis report on Tuesday, July twenty third. Seven funding analysts have rated the inventory with a maintain score, six have issued a purchase score and one has assigned a robust purchase score to the inventory. In response to knowledge from MarketBeat, the inventory has a consensus score of “Average Purchase” and a mean value goal of $173.21.
View Our Newest Analysis Report on Johnson & Johnson
Insider Exercise
In associated information, VP Robert J. Decker offered 5,635 shares of Johnson & Johnson inventory in a transaction dated Friday, August thirtieth. The inventory was offered at a mean value of $165.06, for a complete transaction of $930,113.10. Following the completion of the sale, the vp now owns 18,973 shares of the corporate’s inventory, valued at $3,131,683.38. The transaction was disclosed in a submitting with the Securities & Trade Fee, which is obtainable at the SEC web site. Company insiders personal 0.16% of the corporate’s inventory.
Johnson & Johnson Buying and selling Up 0.5 %
Johnson & Johnson inventory opened at $165.52 on Friday. Johnson & Johnson has a one 12 months low of $143.13 and a one 12 months excessive of $168.85. The inventory has a market cap of $398.45 billion, a PE ratio of 10.32, a price-to-earnings-growth ratio of two.71 and a beta of 0.53. The corporate has a debt-to-equity ratio of 0.44, a fast ratio of 0.85 and a present ratio of 1.07. The inventory has a 50-day transferring common of $159.55 and a two-hundred day transferring common of $154.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final launched its earnings outcomes on Wednesday, July seventeenth. The corporate reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. The corporate had income of $22.45 billion for the quarter, in comparison with the consensus estimate of $22.33 billion. Johnson & Johnson had a web margin of 46.34% and a return on fairness of 36.60%. Johnson & Johnson’s income was up 4.3% in comparison with the identical quarter final 12 months. Throughout the identical quarter within the earlier 12 months, the agency earned $2.80 EPS. On common, analysis analysts anticipate that Johnson & Johnson will publish 10.02 EPS for the present fiscal 12 months.
Johnson & Johnson Dividend Announcement
The corporate additionally lately declared a quarterly dividend, which was paid on Tuesday, September tenth. Shareholders of report on Tuesday, August twenty seventh got a dividend of $1.24 per share. The ex-dividend date was Tuesday, August twenty seventh. This represents a $4.96 dividend on an annualized foundation and a yield of three.00%. Johnson & Johnson’s dividend payout ratio is at the moment 30.92%.
Johnson & Johnson Firm Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare subject worldwide. The corporate’s Revolutionary Medication section gives merchandise for numerous therapeutic areas, resembling immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, resembling prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension via retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Additionally
Wish to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Rankings for Johnson & Johnson Every day – Enter your electronic mail deal with under to obtain a concise day by day abstract of the newest information and analysts’ scores for Johnson & Johnson and associated firms with MarketBeat.com’s FREE day by day electronic mail publication.